A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants

Completed · Phase 1 · Has a placebo group

Conditions studied: Pain

In brief

The purpose of the study is to evaluate the effects of clinical and high clinical exposures of VX-548 and its metabolite on QTcF, and the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VX-548 and its metabolite.

Key facts

Study ID
NCT05818852
Run by
Vertex Pharmaceuticals Incorporated
People needed
72
Starts
2023-04-12
Expected to finish
2023-06-28
Last updated by the study team
2024-03-20

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.